Fintel reports that on October 8, 2024, HC Wainwright & Co. upgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) from ...

Fintel reports that on October 7, 2024, HC Wainwright & Co. initiated coverage of DiaMedica Therapeutics (NasdaqCM:DMAC) with ...

Cassava Sciences (SAVA) stock earns its only buy rating on Wall Street as H.C. Wainwright upgrades the stock citing the company's recent SEC settlement. Read more here.

Equities research analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Rhythm Pharmaceuticals in ...

Pharming Group (NASDAQ:PHAR – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 65.69% ...

On Monday, H.C. Wainwright maintained a Buy rating on Entera Bio (NASDAQ:ENTX), with a price target of $10.00. The firm's stance comes after the recent American Society for Bone and Mineral ...

On Monday, H.C. Wainwright maintained a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a steady price target of $64.00. The firm's confidence in the stock is rooted in the anticipated ...

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report). The associated ...

Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Valneva (VALN – Research Report), reducing the price target to $20.00.

Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The ...